![Troy Ignelzi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Troy Ignelzi
Direttore/Membro del Consiglio presso ABIVAX
Profilo
Troy A.
Ignelzi is currently serving as the Chairman at Vedanta Biosciences, Inc. He is also the Director at Abivax SA, the Independent Director at Contineum Therapeutics, Inc., and the Chief Financial Officer at Rapport Therapeutics, Inc. Previously, Mr. Ignelzi held positions such as Independent Director at CinCor Pharma, Inc., Vice President-Business Development at Esperion Therapeutics, Inc., VP-Business Development & Strategic Planning at InSys Therapeutics, Inc., Chief Financial Officer at Juventas Therapeutics, Inc., Chief Financial Officer at Karuna Therapeutics, Inc., Chief Financial & Accounting Officer at scPharmaceuticals, Inc., and Senior VP-Operations & Business Development at PharmaLex GmbH.
Mr. Ignelzi obtained his undergraduate degree from Ferris State University (Michigan).
Posizioni attive di Troy Ignelzi
Società | Posizione | Inizio |
---|---|---|
ABIVAX | Direttore/Membro del Consiglio | 11/07/2023 |
CONTINEUM THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 20/05/2024 |
Vedanta Biosciences, Inc.
![]() Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Presidente | - |
Rapport Therapeutics, Inc.
![]() Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Direttore Finanziario/CFO | 01/11/2023 |
Precedenti posizioni note di Troy Ignelzi
Società | Posizione | Fine |
---|---|---|
KARA THER | Direttore Finanziario/CFO | 29/09/2023 |
CINCOR PHARMA, INC. | Direttore/Membro del Consiglio | 24/02/2023 |
SCPHARMACEUTICALS INC. | Direttore Finanziario/CFO | 28/02/2019 |
Juventas Therapeutics, Inc.
![]() Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | Direttore Finanziario/CFO | 01/02/2016 |
PharmaLex GmbH
![]() PharmaLex GmbH Packaged SoftwareTechnology Services PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany. | Direttore operativo | 01/10/2014 |
Formazione di Troy Ignelzi
Ferris State University (Michigan) | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 5 |
---|---|
ESPERION THERAPEUTICS, INC. | Health Technology |
SCPHARMACEUTICALS INC. | Health Technology |
ABIVAX | Health Technology |
![]() | Health Technology |
CONTINEUM THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
InSys Therapeutics, Inc. /Old/
![]() InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Health Technology |
Juventas Therapeutics, Inc.
![]() Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | Health Services |
Karuna Therapeutics, Inc.
![]() Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
PharmaLex GmbH
![]() PharmaLex GmbH Packaged SoftwareTechnology Services PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany. | Technology Services |
Vedanta Biosciences, Inc.
![]() Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
CinCor Pharma, Inc.
![]() CinCor Pharma, Inc. Pharmaceuticals: MajorHealth Technology CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Troy Ignelzi